Stockscreener 앱 받기
24.01
3.03%
-0.75
시간 외 거래:
24.00
-0.01
-0.04%
전일 마감가:
$24.76
열려 있는:
$23.95
하루 거래량:
2.90M
Relative Volume:
1.40
시가총액:
$2.88B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-6.125
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
-3.77%
1개월 성능:
+20.53%
6개월 성능:
+57.55%
1년 성능:
+175.34%
1일 변동 폭
$23.85
$24.59
1주일 범위
$23.48
$27.08
52주 변동 폭
$8.45
$27.08
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
24.01 | 3.03B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Goldman | Neutral |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Biotherapeutics Achieves 186.45% Return, Establishing It as a Multibagger in Biotechnology - Markets Mojo
Arcutis Biotherapeutics (ARQT) Reports Positive Safety Data for ZORYVE Foam - GuruFocus
Arcutis Biotherapeutics Reports Long-Term Efficacy and Safety Data for ZORYVE® Foam 0.3% in Treating Seborrheic Dermatitis - Quiver Quantitative
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology - The Manila Times
Arcutis (NASDAQ: ARQT) 52-week Phase 2 OLE: ZORYVE foam shows 80.4% clear/almost clear - Stock Titan
Corton Capital Inc. Acquires New Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Historical volatility pattern of Arcutis Biotherapeutics Inc. visualized2025 Technical Patterns & Safe Capital Growth Trade Ideas - newser.com
What moving averages say about Arcutis Biotherapeutics Inc.July 2025 Retail & Free Reliable Trade Execution Plans - newser.com
Multi asset correlation models including Arcutis Biotherapeutics Inc.Market Trend Report & Weekly Top Stock Performers List - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cutsJuly 2025 Summary & Real-Time Stock Price Movement Reports - newser.com
Leading vs lagging indicators on Arcutis Biotherapeutics Inc. performanceShort Setup & Weekly Chart Analysis and Guides - newser.com
Arcutis Biotherapeutics joins leaders at dermatology conference - Traders Union
Is Arcutis Biotherapeutics Inc. stock undervalued vs historical averages2025 Market Overview & Weekly High Potential Stock Alerts - newser.com
Will earnings trigger a reversal in Arcutis Biotherapeutics Inc.Trade Exit Summary & AI Forecast for Swing Trade Picks - newser.com
Combining price and volume data for Arcutis Biotherapeutics Inc.Share Buyback & Verified Entry Point Detection - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Trends & Community Consensus Trade Alerts - newser.com
Advanced analytics toolkit walkthrough for Arcutis Biotherapeutics Inc.July 2025 Chart Watch & Free Technical Pattern Based Buy Signals - newser.com
Is Arcutis Biotherapeutics Inc. a candidate for recovery play2025 Market Trends & Accurate Buy Signal Alerts - newser.com
How high can Arcutis Biotherapeutics Inc. stock go2025 Trading Volume Trends & AI Driven Stock Price Forecasts - newser.com
Will Arcutis Biotherapeutics Inc. stock deliver consistent dividendsGold Moves & AI Driven Stock Movement Reports - newser.com
Will a bounce in Arcutis Biotherapeutics Inc. offer an exitQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
What’s the recovery path for long term holders of Arcutis Biotherapeutics Inc.Market Performance Recap & Expert Verified Movement Alerts - newser.com
Is Arcutis Biotherapeutics Inc. stock safe for conservative investorsShort Setup & Fast Gain Stock Trading Tips - newser.com
Why hedge funds are buying Arcutis Biotherapeutics Inc. stockJuly 2025 Market Mood & AI Forecasted Entry/Exit Points - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Is Arcutis Biotherapeutics Inc. stock dividend yield sustainableIPO Watch & Free Weekly Chart Analysis and Trade Guides - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to global recession fearsTrend Reversal & Weekly Setup with High ROI Potential - newser.com
HC Wainwright Has Positive Forecast for ARQT FY2025 Earnings - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 40,000 Shares - MarketBeat
Why Arcutis Biotherapeutics (ARQT) Is Up 23.9% After Expanding ZORYVE to Pediatric Atopic Dermatitis - Yahoo Finance
HC Wainwright Has Positive Outlook for ARQT Q4 Earnings - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
What the charts say about Arcutis Biotherapeutics Inc. todayChart Signals & Reliable Price Action Trade Plans - newser.com
Is Arcutis Biotherapeutics Inc. stock poised for growthJuly 2025 Short Interest & AI Enhanced Trade Execution Alerts - newser.com
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):